EVT-101

EVT-101
Clinical data
Other names	ENS-101
Drug class	NMDA receptor antagonist
Identifiers
	IUPAC name 5-[3-(Difluoromethyl)-4-fluorophenyl]-3-[(2-methylimidazol-1-yl)methyl]pyridazine;
CAS Number	627525-33-1 ; 1166398-51-1; 1189088-41-2 (HClTooltip hydrochloride);
PubChem CID	22240172;
ChemSpider	11255877;
UNII	14DN1WB87S;
ChEMBL	ChEMBL3545350;
CompTox Dashboard (EPA)	DTXSID101127745 ;
Chemical and physical data
Formula	C16H13F3N4
Molar mass	318.303 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC=CN1CC2=NN=CC(=C2)C3=CC(=C(C=C3)F)C(F)F;
	InChI InChI=1S/C16H13F3N4/c1-10-20-4-5-23(10)9-13-6-12(8-21-22-13)11-2-3-15(17)14(7-11)16(18)19/h2-8,16H,9H2,1H3; Key:BOVUHBFXPNLTKF-UHFFFAOYSA-N;

EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.^[1] It acts as a selective NMDA receptor subunit 2B (NR2B) antagonist.^[1]^[2] The drug was first claimed by Roche in 2002.^[3] By 2017, EVT-101 was in phase II clinical trials for major depressive disorder; however, development of the drug was discontinued in 2021.^[1]